ALD

Nuclear Fuel from Nuclear Waste: Formation of NewMOX SAS, France

Retrieved on: 
Thursday, April 4, 2024
Electricity, SAS, MOX, Uranium, ALD, Gesellschaft mit beschränkter Haftung, Area studies, Power plant engineering, Evonik Industries, AMG, CO2, Climate change, Nuclear energy, SMR, Plutonium, Coal, Engineering, Uranium mining

Amsterdam, 4 April 2024 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce the formation of NewMOX SAS, Grenoble, France, to service the nuclear fuel market.

Key Points: 
  • Amsterdam, 4 April 2024 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce the formation of NewMOX SAS, Grenoble, France, to service the nuclear fuel market.
  • Presently, the total global storage of civil-use plutonium resulting from the reprocessing of used fuel from commercial nuclear power operations stands at 380 tons, and this figure continues to grow with ongoing nuclear power generation.
  • “We are excited that our furnace technology engineering excellence has created a new project which resulted in the formation of NewMOX SAS.
  • We have appointed Serge Bertrand, head of ALD France, Grenoble, where ALD has centered its nuclear technology activities, to be CEO of NewMOX.

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024
Diuretic, Ultrafiltration, Hospital, Section, Artificial intelligence, Randomized controlled trial, Mount Sinai Health System, Quality of life, Acute decompensated heart failure, Hierarchy, Aquapheresis, Valvular heart disease, Risk, Heart failure, Arrhythmia, AUF, ALD, History, Yale School of Medicine, Patient, HF, Machine learning, Cerebrovascular disease, THT, Mortality, Roflumilast, Pharmaceutical industry

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

Leading Reproductive Expert Dr. Eva Schenkman Takes Helm as Director of Embryology Services at Gattaca Genomics

Retrieved on: 
Tuesday, February 27, 2024
Embryology, Education, IVF, ELD, ABB, Genomics, Entrepreneurship, Andrology, ALD, Genetic testing

Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.

Key Points: 
  • Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.
  • Dr. Schenkman's appointment as Director of Embryology Services signifies Gattaca Genomics' commitment to attracting top-tier talent in the field.
  • In her capacity as Director of Embryology Services, Dr. Schenkman will leverage her extensive experience in IVF laboratory management, andrology, and embryology to lead Gattaca Genomics in pioneering advancements in reproductive health.
  • Michael Carbonara, CEO of Gattaca Genomics says, "Dr. Eva Schenkman's appointment is a testament to Gattaca Genomics' commitment to excellence.

Applied Materials Expands Patterning Solutions Portfolio for Angstrom Era Chipmaking

Retrieved on: 
Monday, February 26, 2024
Engineering, SAN, EUV, Intel, Research, Samsung Electronics, XP, CVD, Carbon, SPIE, Applied Materials, Pioneer, ALD, CMP, Memory, Photon, Process control, EBeam, Logic, Corporation, Printed circuit board

These yield-killing defects are becoming more prevalent as chipmakers implement angstrom era designs with narrower line and space patterns.

Key Points: 
  • These yield-killing defects are becoming more prevalent as chipmakers implement angstrom era designs with narrower line and space patterns.
  • In foundry-logic, Sym3 Y Magnum has already been adopted for critical etch applications at leading chipmakers and is now being deployed for EUV patterning in angstrom era nodes.
  • Since 2012, Applied Materials has made patterning a research and development priority, investing to deliver new products and solutions that help customers overcome their toughest patterning challenges, particularly in emerging EUV and High-NA EUV applications.
  • The company’s patterning product portfolio today includes CVD and ALD deposition; four types of materials removal (etch, selective materials removal, pattern shaping and CMP); thermal processes; and eBeam metrology.

Axiom Cloud Closes $5 Million in Funding to Accelerate Deployment of Refrigerant Leak Detection Software

Retrieved on: 
Tuesday, February 27, 2024
Cloud, SAN, HFC, Leak detection, Hydrofluorocarbon, ROI, ELD, Toshiba, AIM, Entrepreneurship, Refrigeration, Carbon, Climate change, ALD, Head, EPA, CARB, GWP, Leak, Partnership

SAN JOSE, Feb. 27, 2024 /PRNewswire/ -- Axiom Cloud, announced today that it closed $5 million in funding from Toshiba Tec and Windsail Capital Group. This funding aims to accelerate the deployment of the company's AI-powered "Early Leak Detection" (ELD) module, which detects refrigerant leaks earlier without requiring any new onsite hardware or sensors. Axiom Cloud's technology and services will be especially vital as facilities move to comply with recently-announced EPA regulations outlined in the American Innovation and Manufacturing (AIM) Act, which restrict commercial emissions of Hydrofluorocarbons (HFCs) through refrigerant leaks and other sources.

Key Points: 
  • SAN JOSE, Feb. 27, 2024 /PRNewswire/ -- Axiom Cloud , announced today that it closed $5 million in funding from Toshiba Tec and Windsail Capital Group .
  • This funding aims to accelerate the deployment of the company's AI-powered " Early Leak Detection " (ELD) module, which detects refrigerant leaks earlier without requiring any new onsite hardware or sensors.
  • "This is our industry's moment to make a big dent in climate change," said Amrit Robbins, CEO and Co-Founder of Axiom Cloud.
  • "Axiom Cloud can help retailers reduce costs and improve operational efficiency, which we believe can benefit our customers significantly.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Merck, Kidney, USD, POC, Adrenoleukodystrophy, Merck Serono, EPO, JPY, AMN, Sumitomo Pharma, European Patent Convention, Safety, Biomarker, EUR, ALD, ADPKD, Serono, Adenosine, Pharmacokinetics, Patent, Fatty liver disease, Patient, Diabetes, Disease, NASH, Plasma, Male, DSM-IV codes, VLCFA, Pharmaceutical industry

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Retrieved on: 
Sunday, February 4, 2024
Hearing, Inflammation, Civil service commission, Knowledge, European, Cell, Haematopoiesis, COMP, IRIS, Bone marrow, Mitochondrion, Adrenal insufficiency, Regulation, Gland, ABCD1, Patient, Safety, Diagnosis, EMA, ALD, European Commission, Adrenoleukodystrophy, Seizure, B cell, PPAR, Brain, Disease, Therapy, Eurostat, Tissue, Dementia, Medicine, Committee, Hormone, DSM-IV codes, Spinal cord, Pharmaceutical industry

Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Key Points: 


Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive

Ponce De Leon Foundation Announces Grant Awards

Retrieved on: 
Monday, January 29, 2024
Case management, Housing, Little Sisters, LEAP, Access, Family Legal Care, ACE, Mental health, Literacy, Organization, History, POTS, Opportunity, CDC, ALD, HOPE, Owner-occupancy, Education, Comment, Survivor, LGBT Network, Digital literacy, Fast food

BRONX, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of the Ponce De Leon Foundation is pleased to announce it has awarded $622,000 to nonprofits that are making a difference in our communities.

Key Points: 
  • BRONX, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of the Ponce De Leon Foundation is pleased to announce it has awarded $622,000 to nonprofits that are making a difference in our communities.
  • Since its inception in 2017, the Foundation has provided over $2.3 million in grants.
  • Madeline V. Marquez, Executive Director of the Ponce De Leon Foundation, stated “each year the number of applications to our grant program grows by a lot.
  • Act Now Foundation, Inc.: $16,000 for the Alzheimer’s Care Project.

Hitachi Construction Machinery Digital Transformation Strategy Analysis Report 2023: Accelerators, Incubators, and Other Innovation Programs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Other Construction & Property, Machinery, Construction & Property, Manufacturing, ALD, Artificial intelligence, Big data, Hitachi, HCM, Risk, Welding, Acquisition, ICT, Evaluation, 3D, Safety, Robotics, Data analysis, Automation, CAD, FMS, Internet of things, Universal design

The "Hitachi Construction Machinery - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hitachi Construction Machinery - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.
  • This report provides insight into Hitachi Construction Machinery's digital strategies, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.
  • THCM is one of the largest construction equipment manufacturers in India and has manufacturing facilities in Kharagpur and Dharwad.
  • It helps HCM in maintaining a stable supply of construction machinery products that provide safe and durable performance for customers.